207 related articles for article (PubMed ID: 26222319)
1. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Papeo G; Posteri H; Borghi D; Busel AA; Caprera F; Casale E; Ciomei M; Cirla A; Corti E; D'Anello M; Fasolini M; Forte B; Galvani A; Isacchi A; Khvat A; Krasavin MY; Lupi R; Orsini P; Perego R; Pesenti E; Pezzetta D; Rainoldi S; Riccardi-Sirtori F; Scolaro A; Sola F; Zuccotto F; Felder ER; Donati D; Montagnoli A
J Med Chem; 2015 Sep; 58(17):6875-98. PubMed ID: 26222319
[TBL] [Abstract][Full Text] [Related]
2. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
Penning TD; Zhu GD; Gong J; Thomas S; Gandhi VB; Liu X; Shi Y; Klinghofer V; Johnson EF; Park CH; Fry EH; Donawho CK; Frost DJ; Buchanan FG; Bukofzer GT; Rodriguez LE; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
J Med Chem; 2010 Apr; 53(8):3142-53. PubMed ID: 20337371
[TBL] [Abstract][Full Text] [Related]
3. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
4. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
Tang L; Wu W; Zhang C; Shi Z; Chen D; Zhai X; Jiang Y
Bioorg Chem; 2021 Sep; 114():105026. PubMed ID: 34186467
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
8. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
9. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Penning TD; Zhu GD; Gandhi VB; Gong J; Thomas S; Lubisch W; Grandel R; Wernet W; Park CH; Fry EH; Liu X; Shi Y; Klinghofer V; Johnson EF; Donawho CK; Frost DJ; Bontcheva-Diaz V; Bouska JJ; Olson AM; Marsh KC; Luo Y; Rosenberg SH; Giranda VL
Bioorg Med Chem; 2008 Jul; 16(14):6965-75. PubMed ID: 18541433
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lin C; Liu C; Hu P; Zou Z; Sun G
Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective.
Wang R; Cong Y; Li M; Bao J; Qi Y; Zhang JZH
Front Mol Biosci; 2020; 7():50. PubMed ID: 32373627
[TBL] [Abstract][Full Text] [Related]
13. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
15. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Penning TD; Zhu GD; Gandhi VB; Gong J; Liu X; Shi Y; Klinghofer V; Johnson EF; Donawho CK; Frost DJ; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
J Med Chem; 2009 Jan; 52(2):514-23. PubMed ID: 19143569
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
[TBL] [Abstract][Full Text] [Related]
20. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
